Many MindedFirst patients dosed with an epigenetic reprogramming gene therapy for glaucoma
On October 27, 2026, Life Biosciences released interim results from the first-in-human Phase 1 trial of ER-100 in open angle glaucoma (NCT07290244). Three participants each received a single intravitreal dose at Dose Level 1 (2×10^11 vg), plus daily oral doxycycline. Through Day 56, the therapy was well tolerated in all three. The company reports no dose-limiting toxicities, no adverse events of special interest and no serious adverse events. Events that did occur were attributed to the procedure, steroid use or pre-existing conditions, not directly to ER-100. The Data Safety Monitoring Board has recommended moving to Dose Level 2 (6×10^11 vg), and the trial continues.
ER-100 delivers three transcription factors, OCT4, SOX2 and KLF4 (together OSK), in one injection. Doxycycline switches their expression on for eight weeks (56 days). An oral prednisolone taper is given to limit inflammation from the immune response to the AAV-2 delivery vector. Two of the three participants improved on Humphrey Visual Field testing at Day 56. In each, at least 28% of visual field points improved by more than 4 dB.
This matters because partial epigenetic reprogramming is a way to treat age-related disease by resetting cell function rather than managing symptoms. Until now it has had little human safety evidence. If it holds up, one treatment course could replace lifelong management of conditions like glaucoma. The company's stated targets are open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).
The caveats are large. Three participants, interim data to Day 56, an open-label design, and company-reported results from a press release. Phase 1 is built to test safety and tolerability, not efficacy, so the visual field gains are preliminary. Watch for Dose Level 2 results and larger, longer follow-up.
Source: Lifespan.io